English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, January 18, 2023
Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
エーザイ、米国臨床腫瘍学会消化器がんシンポジウム2023において消化器系がんに対する治療薬の最新の開発研究の演題を発表
Monday, January 16, 2023
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、日本において早期アルツハイマー病に係る適応で新薬承認を申請
Friday, January 13, 2023
エーザイ、サステナビリティページ リニューアルのお知らせ
Eisai Launches Renewed Sustainability Page
Wednesday, January 11, 2023
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe
エーザイ、抗アミロイドβプロトフィブリル抗体「レカネマブ」について、欧州において早期アルツハイマー病に係る適応で販売承認申請を提出
Monday, January 9, 2023
Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575